Article info
PDFReview
Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine
- Correspondence to Dr Nicola J Giffin, Neurology, Royal United Hospital, Bath, BA1 3NG, UK; Nicola.giffin{at}nhs.net
Citation
Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine
Publication history
- Accepted January 18, 2023
- First published February 8, 2023.
Online issue publication
May 25, 2023
Article Versions
- Previous version (8 February 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Three new drugs for the prevention of migraine
- Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series
- Management of chronic migraine
- Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects
- Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial
- Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study
- Chronic migraine
- Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study
- 4CPS-354 Efficacy and safety with erenumab and galcanezumab: our experience
- CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab